SAVA logo

Cassava Sciences, Inc.


SAVA: Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms.


Show SAVA Financials

Consumer Interest
SEC Filings

Recently reported changes by institutional investors

Quarterly net insider trading by SAVA's directors and management

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Method of inhibiting tau phosphorylation May. 30, 2023
  • Patent Title: Solid polymorphs of a flna-binding compound and its hydrochloride salts Jun. 28, 2022
  • Patent Title: Cocrystals of naloxone and naltrexone Aug. 24, 2021
  • Patent Title: Method of inhibiting tau phosphorylation Sep. 01, 2020
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard

Number of mentions of SAVA in WallStreetBets Daily Discussion


Recent insights relating to SAVA

CNBC Recommendations

Recent picks made for SAVA stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in SAVA

Corporate Flights

Flights by private jets registered to SAVA